Immunotherapy
The authors provide a brief background and an overview of cancer vaccine therapy, current research, clinical application, and current challenges.
Immune checkpoint inhibitors (ICIs) have become a mainstay in the treatment of a variety of malignancies and are well-known as effective cancer therapies.
Chimeric antigen receptor (CAR) T-cell (CAR-T for short) products have the power and the potential to cure, according to Kathleen McDermott, RN, BSN, OCN, BMTCN, from Dana-Farber Cancer Institute in Boston.
For some patients, the use of CAR-T cell therapy has resulted in robust and durable (>95%) responses lasting longer than 5 years. Here’s what you need to know about CAR T-cell therapy.
Historically, surgery, chemotherapy, and radiation have been the mainstay of most cancer therapies. Although these modalities have been successful and improved survival outcomes, cancer remains one of the most debilitating diagnoses, often with poor outcomes.
The FDA has granted priority review to Merck’s supplemental Biologics License Application for the anti-PD–1 agent pembrolizumab as monotherapy for certain patients with high-risk, non-muscle invasive bladder cancer who are ineligible for or have elected not to undergo cystectomy.
Reprogramming patients’ immune cells to treat their cancer has become the front line of cancer therapy, with chimeric antigen receptor (CAR) T-cell therapy now approved by the FDA for several blood cancers.
Moving combination immunotherapy into the neoadjuvant setting for patients with stage III melanoma induces a higher rate of pathologic response than adjuvant therapy, said Christian U. Blank, MD, PhD, Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium.
Carsten Kampe, MD, PhD, discusses the excitement surrounding immunotherapy at the AONN+ Annual Conference
Immunotherapy drugs work by boosting the immune system so that a person’s own immune system works smarter to identify and destroy any cancer cells.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512